肠病性脊柱关节炎从高危到早期的连续谱
本综述整合流行病学、影像与生物标志物证据,提出肠病性脊柱关节炎存在从高危状态、亚临床影像学炎症到早期临床关节炎的连续谱,机制涉及3型免疫、菌群失调、上皮屏障障碍及遗传易感。作者建议在炎症性肠病管理中采用兼顾肠道与关节的双间室精准策略,包括结构化骨骼肌肉筛查、概率引导影像和及时使用具有肠-关节疗效的药物。
要点
- 肠病性脊柱关节炎是炎症性肠病常见但被低估的肌肉骨骼表现,可导致长期残疾。
- 从高危到早期临床关节炎的连续谱包括亚临床MRI/超声骶髂关节及附着点炎症。
- 建议采用双间室精准策略,整合筛查、概率引导影像和肠-关节疗效药物。
核心结论
- 肠病性脊柱关节炎存在从高危状态到早期临床关节炎的连续谱,应被视为可干预、达标治疗的表型。
研究设计与样本
- 本综述综合机制与临床证据,覆盖高危个体、亚临床肌肉骨骼疾病个体及早期临床关节病患者。
主要发现
- 从高危状态经亚临床MRI或超声定义的骶髂关节及附着点炎症,进展至早期临床肠病性脊柱关节炎,常伴明显滑膜炎、附着点炎和炎性背痛。
- 该转变发生在肠道来源炎症环境中,涉及3型免疫、菌群失调、上皮屏障功能障碍、肠道归巢及组织驻留淋巴细胞回路和多基因易感。
- 肠道与肌肉骨骼轨迹仅部分同步,临床呈现阶段特异性特征,粪便钙卫蛋白、C反应蛋白和HLA-B27为概率性修饰因素。
- 能量多普勒超声和骶髂关节或脊柱MRI可在不可逆结构改变前识别炎症。
临床怎么用
- 在炎症性肠病管理中整合结构化肌肉骨骼筛查、概率引导影像和及时使用具有肠-关节疗效证据的药物。
- 采用兼顾肠道和关节的双间室精准策略,以预防诊断延迟、限制结构损伤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Enteropathic spondyloarthritis is a common, under-recognised musculoskeletal manifestation of inflammatory bowel disease and a potentially preventable contributor to long-term disability. Epidemiological, imaging, and biomarker data support a continuum from at-risk states (ie, high-risk inflammatory bowel disease phenotypes with early extraintestinal manifestations and non-specific pain), through subclinical MRI-defined or ultrasound-defined sacroiliac and entheseal inflammation, to early clinical enteropathic spondyloarthritis with overt synovitis, enthesitis, and inflammatory back pain, often after prolonged diagnostically ambiguous symptoms. This transition unfolds within a gut-derived inflammatory milieu shaped by type-3 immunity, dysbiosis, epithelial barrier dysfunction, gut-homing and tissue-resident lymphocyte circuits, and polygenic susceptibility, with only partial synchrony between intestinal and musculoskeletal trajectories. Clinically, these mechanisms yield phase-specific signatures in which faecal calprotectin, C-reactive protein, and HLA-B27 act as probabilistic modifiers, and power Doppler ultrasound and sacroiliac or spinal MRI enable recognition of inflammation before irreversible structural change. In this Review, we synthesise mechanistic and clinical evidence across the at-risk-to-early articular continuum (this term refers to individuals at-risk of enteropathic spondyloarthritis, individuals with subclinical musculoskeletal disease, and patients with early clinical articular disease). We propose a precision, dual-compartment strategy addressing both gut and joint involvement, integrating structured musculoskeletal screening, probability-guided imaging, and timely use of therapies with proven gut-joint efficacy into inflammatory bowel disease care, aiming to prevent diagnostic delay, limit structural damage, and reframe enteropathic spondyloarthritis as an interceptable, treat-to-target phenotype along the gut-joint axis.
引用
- Caso F, Nardone OM, Costa L, et al. The at-risk-to-early continuum of enteropathic spondyloarthritis. Lancet Rheumatol. 2026. PMID: 42330993. doi:10.1016/S2665-9913(26)00087-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。